MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Diabetes Treatment and Management
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,896 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,896 works in the cohort · of 4,299,418page 13 of 78

Labels cover 11 of 3,896 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,896 of 3,896 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Novel Diabetes Drugs and the Cardiovascular Specialist
Naveed Sattar, Mark C. Petrie, Bernard Zinman, James L. Januzzi
2017· review· en· Journal of the American College of Cardiology· Medicine
machine prediction:candidate · noneconsensus · none
84
citations
affunlabeled
Weight Beneficial Treatments for Type 2 Diabetes
L. F. Meneghini, Domingo Orozco‐Beltrán, Kamlesh Khunti, Salvatore Caputo, Andreas Liebl, S. A. Ross
2011· review· en· The Journal of Clinical Endocrinology & Metabolism· Medicine
machine prediction:candidate · noneconsensus · none
83
citations
venueno affno abstractunlabeled
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
Gillian L. Booth, Lorraine L. Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Ronald Goldenberg +5 more
2016· article· en· Canadian Journal of Diabetes· Medicine
machine prediction:candidate · noneconsensus · none
83
citations
affunlabeled
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael Pencina +11 more
2018· article· en· Cardiovascular Diabetology· Medicine
machine prediction:candidate · noneconsensus · none
83
citations
affunlabeled
Semaglutide and NT-proBNP in Obesity-Related HFpEF
Mark C. Petrie, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Sanjiv J. Shah +12 more
2024· article· en· Journal of the American College of Cardiology· Medicine
machine prediction:candidate · noneconsensus · none
82
citations
afffundunlabeled
Antipsychotics and glucose metabolism: how brain and body collide
Chantel Kowalchuk, L Castellani, Araba Chintoh, Gary Remington, Adria Giacca, Margaret Hahn
2018· review· en· American Journal of Physiology-Endocrinology and Metabolism· Medicine
machine prediction:candidate · noneconsensus · none
80
citations

How this was built: Screen · Findings · About